We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 949

Federal Circuit Clarifies Probative Value of Patent Dance Statements
  • Jones Day
  • USA
  • November 27 2017

The Biologics Price Competition and Innovation Act was considered in a November 2017 decision by the United States Court of Appeals for the Federal C


The Federal Circuit Affirms: The Apotex Filgrastim (Neupogen) and Pegfilgrastim (Neulasta) Litigation
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • November 21 2017

Several of the Federal Circuit’s initial decisions involving the Biologics Price Competition and Innovation Act (the “BPCIA”) focused on unpacking the


Competition proceedings ended with TEVA's commitments
  • CMS Cameron McKenna Nabarro Olswang LLP
  • Hungary
  • November 15 2017

After launching competition proceedings against the pharmaceutical company TEVA Gyógyszergyár Zrt. (“TEVA”) two years ago, the Hungarian Competition


Anti-Corruption Quarterly - 3rd quarter 2017
  • Sidley Austin LLP
  • USA, United Kingdom
  • November 7 2017

The healthcare industry is no stranger to Department of Justice (DOJ) scrutiny. DOJ prosecutors have aggressively pursued improper billing practices


Federal Judge and U.S. Senators Weigh in as PTAB Considers Tribal Sovereign Immunity Defense in IPR Proceeding
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • October 16 2017

Senior U.S. Circuit Judge William Bryson ruled on Monday that all the asserted claims in the six Restasis patents that Allergan PLC ("Allergan"


America’s Opioid Epidemic: Who Will Be Held Accountable?
  • Husch Blackwell LLP
  • USA
  • October 11 2017

In recent years America has seen an increasing number of opioid-involved deaths and is currently experiencing what the Center for Disease Control


Indian Tribal Sovereign Immunity Asserted in an IPR
  • Seyfarth Shaw LLP
  • USA
  • September 25 2017

The America Invents Act (“AIA”) provides for post grant challenges of U.S. patents in the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent


Health Care Companies Take Note: DOJ Ramps Up FCPA Enforcement
  • Cadwalader Wickersham & Taft LLP
  • USA
  • September 1 2017

In July, we reported on Attorney General Sessions dismantling DOJ's Health Care Corporate Fraud Strike Force. On July 25, Sandra Moser, acting chief


Washington Healthcare Update - Aug 28, 2017
  • McGuireWoods LLP
  • USA
  • August 28 2017

On Aug. 17, Reps. Peter Welch (D-VT) and Elijah Cummings (D-MD) sent letters to seven drug companies in an effort to gather information on profits


Federal Court of Appeal remits decision based on hearsay evidence back to the Federal Court for redetermination
  • PCK Perry + Currier Inc Currier + Kao LLP
  • Canada
  • August 22 2017

Stakes can be very high in patent lawsuits, compelling parties to include as much evidence in their favour as possible. However, as with any type of